Pharmacokinetics of the Soluble Guanylate Cyclase Activator Cinaciguat in Individuals With Hepatic Impairment

CINACIGUAT, A SOLUBLE GUANYLATE CYCLASE ACTIVATOR, UNLOADS THE HEART IN ACUTE DECOMPENSATED HEART FAILURE

(2010) Erland Erdmann et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure

(2009) Harald Lapp et al.   CIRCULATION

Drug Uptake Systems in Liver and Kidney: A Historic Perspective

(2009) B Hagenbuch   CLINICAL PHARMACOLOGY & THERAPEUTICS

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

(2009) Sharon Ann Hunt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)

(2008) et al.   EUROPEAN HEART JOURNAL

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

(2008) Roger K. Verbeeck   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58-2667) in Healthy Male Volunteers

(2008) Reiner Frey et al.   JOURNAL OF CLINICAL PHARMACOLOGY